Zepbound Savings Card in 2026: Eligibility, Limits and How to Apply

Eli Lilly offers a savings card that can bring the Zepbound copay down to $25 per month for commercially insured patients. The card also has a self-pay track for KwikPens at retail pharmacies. Below is a step-by-step walkthrough of both programs, the eligibility rules that trip people up, and what to do when the card gets rejected at the counter.

How the Zepbound Savings Card Works

With Commercial Insurance ($25 Copay)

If your employer-sponsored or marketplace plan covers Zepbound, the savings card reduces your out-of-pocket copay to as low as $25 per month (zepbound.lilly.com/savings, October 2026). Lilly pays the difference between your copay and $25, subject to monthly and annual caps. The monthly cap is $100 for a one-month fill, $200 for a two-month fill, or $300 for a three-month fill. The annual cap is $1,300 per calendar year. The card expires December 31, 2026.

This means the card works best when your insurance copay is moderate. If your plan sets the copay at $125 per month, the card covers $100 of that and you pay $25. If the copay is $400, the card still covers only $100, and you pay $300. Patients whose plans have very high copays or coinsurance should run the math before assuming the card solves the cost problem.

Without Insurance (Self-Pay Pricing)

Lilly also offers a separate self-pay savings card for Zepbound KwikPens at retail pharmacies. This is not the same as the LillyDirect vial program. The KwikPen self-pay prices are: 2.5 mg at $299 per month, 5 mg at $399 per month, and 7.5 mg through 15 mg at $449 per month (zepbound.lilly.com/savings, October 2026). These prices apply at participating retail pharmacies when you present the self-pay card.

The retail self-pay card is a separate program from the insured $25 copay card. You cannot use both simultaneously. If you have insurance that does not cover Zepbound at all, the self-pay KwikPen card or the LillyDirect vial program are your two main options.

Eligibility Rules and Exclusions

The insured savings card requires that you carry commercial insurance and that your plan covers Zepbound. "Commercial" means employer-sponsored, ACA marketplace, or individually purchased private insurance. The card cannot be used with Medicare, Medicaid, VA benefits, TRICARE, or any other federal or state government-funded insurance program. Patients enrolled in these programs are categorically excluded regardless of income or coverage status.

Mounjaro Savings Card: Same Drug, Different Program

Mounjaro contains the same active ingredient as Zepbound but is approved for type 2 diabetes rather than weight management. Lilly runs a separate savings card for Mounjaro with slightly different terms (mounjaro.lilly.com/savings-resources, October 2026). The table below compares the two programs side by side.

The Mounjaro card offers higher monthly and annual caps. If your physician prescribes Mounjaro for diabetes and your plan covers it, the Mounjaro card provides up to $1,950 in annual savings versus $1,300 for Zepbound. Both expire at the end of 2026. For patients with a diabetes diagnosis, Mounjaro often has broader formulary acceptance, which makes the savings card more likely to apply in the first place. See our tirzepatide cost overview for a complete price comparison across all routes.

Who Cannot Use These Savings Cards

Medicare and Medicaid Beneficiaries

Federal law prohibits manufacturer copay cards from being used with government health programs. If you are enrolled in Medicare Part D, Medicaid, or a dual-eligible plan, neither the Zepbound nor the Mounjaro savings card will work. The pharmacy system will reject the card automatically when it detects a government payer in the claims adjudication.

Government-Funded Insurance

The exclusion extends beyond Medicare and Medicaid. VA benefits, TRICARE, the Department of Defense CHAMPUS program, and any state-funded pharmaceutical assistance program are all excluded. If your coverage is paid for by any level of government, the savings card does not apply.

The $50 Medicare GLP-1 Bridge Alternative

For Medicare enrollees specifically, Lilly offers the GLP-1 Bridge program through LillyDirect. Eligible Medicare Part D patients can get tirzepatide for $50 per month, a flat rate regardless of dose. This is a manufacturer-sponsored program, not a Part D benefit. Eligibility requires active Part D enrollment and a valid prescription. It is the only Lilly discount pathway available to Medicare patients. For a broader view of low-cost options, including compounded tirzepatide, see our cheapest tirzepatide ranking.

Common Problems and How to Fix Them

Pharmacy Says the Card Is Rejected

The most common reason for rejection is an insurance mismatch. If your primary insurance is government-funded, the card will not process. The second most common cause is data entry errors at the pharmacy counter. Ask the pharmacist to verify the BIN, PCN, group number, and member ID against what appears on your card. Transposed digits in any of those fields will trigger a rejection. If everything matches and the card still fails, call the number on the back of the card. Lilly's support line can troubleshoot the claim in real time while you are at the pharmacy.

Maximum Annual Savings Reached

Once you hit the $1,300 annual cap on the Zepbound card (or $1,950 on the Mounjaro card), the card stops providing any discount for the rest of the calendar year. The caps reset on January 1. If you hit the ceiling partway through the year, your remaining fills will process at whatever your insurance copay is without the savings card subsidy. Patients who fill monthly and have copays around $100 will typically reach the $1,300 Zepbound cap in about 13 months, meaning the cap is unlikely to bind within a single calendar year. Patients with higher copays could exhaust it sooner.

Insurance Formulary Dropped Zepbound

Formulary changes happen at the start of each plan year or sometimes mid-year. If your insurer removes Zepbound from the formulary, the insured savings card stops working because there is no covered copay for the card to reduce. At that point, your options are: switch to the self-pay KwikPen card at $299 to $449 per month, use LillyDirect self-pay vials at similar prices, ask your prescriber about Mounjaro if you have a diabetes diagnosis and that drug remains on formulary, or explore compounded tirzepatide as a lower-cost alternative.